Literature DB >> 10335684

Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.

A G Bostom1, H Silbershatz, I H Rosenberg, J Selhub, R B D'Agostino, P A Wolf, P F Jacques, P W Wilson.   

Abstract

BACKGROUND: Elevated fasting total homocysteine (tHcy) levels were recently shown to confer an independent risk for all-cause and cardiovascular disease (CVD) mortality among selected Norwegian patients with confirmed coronary heart disease. We examined whether elevated fasting plasma tHcy levels were predictive of all-cause and CVD mortality in a large, population-based sample of elderly US women and men.
METHODS: Nonfasting plasma tHcy levels were determined in 1933 elderly participants (mean age, 70 +/- 7 years; 58.9% women) from the original Framingham Study cohort, examined between 1979 and 1982, with follow-up through 1992. Unadjusted and adjusted (ie, for age, sex, diabetes, smoking, systolic blood pressure, total and high-density lipoprotein cholesterol, and creatinine) relative risk estimates (with 95% confidence intervals [CIs]) for total and CVD mortality were generated by proportional hazards modeling, with tHcy levels (quartiles) as the independent variable.
RESULTS: There were 653 total deaths and 244 CVD deaths during a median follow-up of 10.0 years. Proportional hazards modeling revealed that tHcy levels of 14.26 micromol/L or greater (the upper quartile), vs less than 14.26 micromol/L (the lower three quartiles), were associated with relative risk estimates of 2.18 (95% CI, 1.86-2.56) and 2.17 (95% CI, 1.68-2.82) for all-cause and CVD mortality, respectively. The relative risk estimates after adjustment for age, sex, systolic blood pressure, diabetes, smoking, and total and high-density lipoprotein cholesterol levels attenuated these associations, but they remained significant: 1.54 (95% CI, 1.31-1.82) for all-cause mortality; 1.52 (95% CI, 1.16-1.98) for CVD mortality.
CONCLUSION: Elevated nonfasting plasma tHcy levels are independently associated with increased rates of all-cause and CVD mortality in the elderly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335684     DOI: 10.1001/archinte.159.10.1077

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  51 in total

Review 1.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Homocysteine: a sulph'rous fire.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

3.  Elevated homocysteine: a new marker for dementia?

Authors:  Katheryn A Myers
Journal:  CMAJ       Date:  2002-04-16       Impact factor: 8.262

4.  Vitamin B12 status, homocysteine and mortality amongst community-dwelling Irish elders.

Authors:  D J Robinson; C O'Luanaigh; E Tehee; H O'Connell; F Hamilton; A V Chin; R Coen; A M Molloy; J Scott; B A Lawlor; C J Cunningham
Journal:  Ir J Med Sci       Date:  2010-11-13       Impact factor: 1.568

Review 5.  An update on treatment and prevention strategies for Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

6.  Connective tissue: Vascular and hematological (blood) support.

Authors:  Nick Calvino
Journal:  J Chiropr Med       Date:  2003

7.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

Review 8.  Homocysteine lowering with folic acid and vitamin B supplements: effects on cardiovascular disease in older adults.

Authors:  Cynthia M Carlsson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 9.  Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease.

Authors:  Federico Cacciapuoti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

10.  Differences in heterocycle basicity distinguish homocysteine from cysteine using aldehyde-bearing fluorophores.

Authors:  Aabha Barve; Mark Lowry; Jorge O Escobedo; Katherine T Huynh; Lovemore Hakuna; Robert M Strongin
Journal:  Chem Commun (Camb)       Date:  2014-08-04       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.